The noradrenergic system mediates arousal, attention, autonomic sympathetic output, and stress response. In neurology, adrenergic pharmacology spans cardiovascular management (acute stroke blood pressure, autonomic dysfunction), ADHD treatment, migraine prophylaxis, essential tremor, sympathetic blockade in autonomic neurology, and the management of pheochromocytoma and other rare hypertensive crises. This page covers the receptor anatomy, drug classes, and clinical applications.

Noradrenergic Anatomy

Central

  • Locus coeruleus: rostral pons; primary CNS noradrenergic nucleus; projects widely to cortex, hippocampus, cerebellum, spinal cord; arousal, attention.
  • Lateral tegmental neurons: additional brainstem source.
  • Noradrenergic neurons release norepinephrine and (in some) co-transmitters.

Peripheral

  • Sympathetic postganglionic neurons: release norepinephrine at effector organs.
  • Adrenal medulla: releases epinephrine (and some norepinephrine) into bloodstream.

Adrenergic Receptors

α (alpha) Receptors

  • α1: Gq-coupled; vasoconstriction (vascular smooth muscle), urinary sphincter contraction. Targets: phenylephrine, prazosin (antagonist).
  • α2: Gi-coupled; presynaptic autoreceptors (decrease NE release); CNS sedation. Targets: clonidine, dexmedetomidine, guanfacine (agonists).

β (beta) Receptors

  • β1: Gs-coupled; cardiac (rate, contractility); renin release. Targets: metoprolol, atenolol (selective antagonists); dobutamine (agonist).
  • β2: Gs-coupled; smooth muscle relaxation (bronchodilation, vasodilation in skeletal muscle), uterine relaxation, hepatic glycogenolysis. Targets: salbutamol, albuterol (agonists).
  • β3: Gs-coupled; adipose tissue (lipolysis), bladder detrusor relaxation. Targets: mirabegron (agonist, OAB).

Catecholamine Synthesis and Metabolism

  • Tyrosine → DOPA (tyrosine hydroxylase; rate-limiting) → dopamine (DOPA decarboxylase) → norepinephrine (dopamine β-hydroxylase, in vesicles).
  • Stored in vesicles via vesicular monoamine transporter (VMAT2).
  • Release: Ca²⁺-dependent exocytosis.
  • Reuptake: norepinephrine transporter (NET); high-affinity, primary clearance.
  • Metabolism: MAO (in mitochondria), COMT (extraneuronal); final metabolite vanillylmandelic acid (VMA).

Major Drug Classes

α-Adrenergic Agonists

  • Phenylephrine: pure α1 agonist; vasoconstrictor; hypotension management; nasal decongestant; mydriatic.
  • Pseudoephedrine: mixed α/β agonist; nasal decongestant; can increase BP, worsen autonomic dysreflexia in spinal cord patients.
  • Midodrine: α1 agonist; orthostatic hypotension treatment (autonomic neuropathy, neurogenic orthostasis).
  • Clonidine: α2 agonist; CNS-mediated BP lowering, ADHD adjunct, restless legs syndrome.
  • Dexmedetomidine: α2 agonist; ICU sedation (preserves arousal), procedural sedation.
  • Guanfacine: α2 agonist; ADHD, Tourette syndrome, anxiety.
  • Tizanidine: α2 agonist; spasticity treatment.

α-Adrenergic Antagonists

  • Prazosin, terazosin, doxazosin: α1 antagonists; BPH (urinary symptoms), hypertension (rarely), PTSD nightmares.
  • Tamsulosin: α1a-selective; BPH; minimal BP effect.
  • Phentolamine: nonselective α antagonist; hypertensive crisis from pheochromocytoma; tyramine-induced crisis.
  • Phenoxybenzamine: irreversible α antagonist; preoperative pheochromocytoma management.

β-Adrenergic Antagonists (Beta Blockers)

  • Cardioselective (β1): metoprolol, atenolol, bisoprolol.
  • Non-selective: propranolol, nadolol, timolol.
  • Mixed α/β: labetalol, carvedilol.
  • ISA (intrinsic sympathomimetic activity): pindolol, acebutolol; less bradycardia at rest.
  • Uses in neurology:
    • Essential tremor (propranolol; nadolol if propranolol not tolerated).
    • Migraine prophylaxis (propranolol, timolol, metoprolol, nadolol).
    • Performance anxiety (propranolol).
    • Akathisia (propranolol).
    • Hypertension in stroke (labetalol IV for acute BP reduction).
    • Tachyarrhythmia in autonomic dysfunction.
  • Side effects: bradycardia, fatigue, depression, bronchospasm (β2-mediated in non-selective), cold extremities, masked hypoglycemia.
  • Contraindications: severe asthma, severe COPD, advanced AV block, decompensated CHF (with caveats).

β-Adrenergic Agonists

  • Albuterol, salbutamol, terbutaline: β2 agonists; bronchodilators; CAN cause tremor.
  • Dobutamine: β1 agonist; cardiac stimulation; ICU.
  • Mirabegron: β3 agonist; overactive bladder (alternative to anticholinergics; less cognitive side effects).
  • Epinephrine: nonselective agonist; anaphylaxis (α1 vasoconstriction + β1 cardiac + β2 bronchodilation); cardiac arrest.
  • Norepinephrine: vasopressor in shock; primarily α1 vasoconstriction with β1 cardiac.

Norepinephrine Reuptake Inhibitors

  • Atomoxetine: selective NE reuptake inhibitor; ADHD.
  • Viloxazine: NRI; ADHD.
  • Reboxetine, mazindol: less commonly used.
  • SNRIs: venlafaxine, duloxetine, desvenlafaxine; for depression, anxiety, neuropathic pain, fibromyalgia.
  • Tricyclic antidepressants: NE + serotonin reuptake inhibition; neuropathic pain (amitriptyline, nortriptyline); migraine prophylaxis.
  • Bupropion: dopamine/NE reuptake inhibition; depression, ADHD adjunct, smoking cessation.

Stimulants

  • Methylphenidate, dextroamphetamine, lisdexamfetamine: increase synaptic DA and NE (transporter reversal, vesicle release).
  • ADHD treatment.
  • Narcolepsy.
  • Cognitive enhancement (off-label, controversial).
  • Adverse: tachycardia, hypertension, insomnia, appetite suppression, tics, psychiatric effects, growth concerns in children.

Clinical Applications by Condition

Essential Tremor

  • First-line: propranolol 60-240 mg/day, primidone 50-250 mg/day.
  • Second-line: topiramate, gabapentin.
  • Surgical: DBS (Vim thalamic), focused ultrasound thalamotomy.

Migraine Prophylaxis

  • Propranolol, timolol, metoprolol, nadolol (β-blockers).
  • Amitriptyline, nortriptyline (TCAs).
  • Venlafaxine (SNRI).
  • Calcium channel blockers (verapamil, flunarizine).
  • Topiramate, valproate.
  • Anti-CGRP monoclonals (newer).

ADHD

  • Stimulants: methylphenidate, amphetamine derivatives.
  • Non-stimulants: atomoxetine (NRI), viloxazine (NRI), guanfacine ER, clonidine ER.
  • Atomoxetine takes 4-6 weeks for full effect; stimulants act within hours.

Orthostatic Hypotension

  • Non-pharm: salt, fluid, head-of-bed elevation, abdominal binder, compression.
  • Pharm: fludrocortisone (mineralocorticoid), midodrine (α1 agonist), droxidopa (NE prodrug), pyridostigmine (improved with standing).
  • Autonomic neuropathies, MSA, PD with autonomic dysfunction.

Acute Stroke BP Management

  • Hemorrhagic stroke: target SBP 130-150; labetalol or nicardipine IV.
  • Ischemic stroke pre-thrombolytic: SBP <185 / DBP <110; labetalol or nicardipine IV.
  • Permissive hypertension (in non-thrombolytic candidate AIS); allows perfusion.

Autonomic Dysreflexia (Spinal Cord Injury)

  • Massive sympathetic response to noxious stimulus below T6 lesion → severe hypertension, headache, sweating.
  • Treatment: position upright, identify trigger (often bladder, bowel), nitrates, fast-acting antihypertensives.

Pheochromocytoma

  • Preop: α-blockade (phenoxybenzamine or doxazosin) — start first.
  • Then β-blockade ONLY after α-blockade (avoid unopposed α stimulation → hypertensive crisis).
  • Surgery.

🔍 Did You Know?

The principle of α-blockade before β-blockade in pheochromocytoma is one of the most clinically critical sequencing rules in pharmacology. A patient with pheochromocytoma has excess circulating catecholamines acting on both α and β receptors. If a β-blocker is given first, the cardiac (β1) effects are blocked, but α-mediated vasoconstriction remains UNOPPOSED, leading to severe peripheral vasoconstriction and potentially catastrophic hypertensive crisis. The correct sequence is: phenoxybenzamine (or doxazosin) starting weeks before surgery to achieve α-blockade and allow volume expansion, then β-blocker after α-blockade is established to control reflex tachycardia. The same principle applies to other catecholamine-excess states: cocaine intoxication-induced hypertension is managed with α-blockers (phenoxybenzamine or labetalol) rather than pure β-blockers; tyramine-induced crisis from MAOI interaction also benefits from α-blockade. The lesson generalizes: understanding receptor pharmacology prevents iatrogenic harm, and the apparently simple act of “lowering blood pressure” requires knowing which receptors are driving the elevation. For the practicing neurologist, this principle matters in autonomic dysfunction, pheochromocytoma evaluation, and the rare encounter with stimulant overdose or MAOI interaction.

Pitfalls and Pearls

  • α1: vasoconstriction (phenylephrine, midodrine agonists; prazosin antagonist).
  • α2: presynaptic autoinhibition + CNS sedation (clonidine, dexmedetomidine, guanfacine agonists).
  • β1: cardiac (metoprolol, atenolol antagonists).
  • β2: bronchodilation, vasodilation (albuterol agonist; can cause tremor).
  • β3: bladder relaxation (mirabegron for OAB).
  • Propranolol: essential tremor, migraine prophylaxis, performance anxiety, akathisia.
  • Labetalol IV: acute stroke BP management.
  • Phenoxybenzamine before β-blocker in pheochromocytoma; β alone causes unopposed α → crisis.
  • Midodrine: α1 agonist; orthostatic hypotension; avoid supine to prevent supine hypertension.
  • Droxidopa: NE prodrug for neurogenic orthostatic hypotension.
  • Stimulants for ADHD: methylphenidate, amphetamines; rapid effect; cardiac concerns.
  • Atomoxetine: non-stimulant ADHD; 4-6 weeks for effect.
  • Clonidine, guanfacine: α2 agonists; ADHD, hypertension, Tourette.
  • Tizanidine: α2 agonist; spasticity.
  • Beta-blockers: avoid in severe asthma, advanced AV block.
  • SNRI/TCA for neuropathic pain: duloxetine, amitriptyline.

References

  1. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill; 2023.
  2. Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function. Annu Rev Neurosci. 2005;28:403-450.
  3. Low PA, Tomalia VA, Park KJ. Autonomic function tests: some clinical applications. J Clin Neurol. 2013;9(1):1-8.
  4. Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4):973-989.
  5. Hopfer CJ, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat. 2002;23(3):231-237.